Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Infect Immun ; 81(11): 4220-31, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24002059

RESUMO

VirF is an AraC family transcriptional activator that is required for the expression of virulence genes associated with invasion and cell-to-cell spread by Shigella flexneri, including multiple components of the type three secretion system (T3SS) machinery and effectors. We tested a small-molecule compound, SE-1 (formerly designated OSSL_051168), which we had identified as an effective inhibitor of the AraC family proteins RhaS and RhaR, for its ability to inhibit VirF. Cell-based reporter gene assays with Escherichia coli and Shigella, as well as in vitro DNA binding assays with purified VirF, demonstrated that SE-1 inhibited DNA binding and transcription activation (likely by blocking DNA binding) by VirF. Analysis of mRNA levels using real-time quantitative reverse transcription-PCR (qRT-PCR) further demonstrated that SE-1 reduced the expression of the VirF-dependent virulence genes icsA, virB, icsB, and ipaB in Shigella. We also performed eukaryotic cell invasion assays and found that SE-1 reduced invasion by Shigella. The effect of SE-1 on invasion required preincubation of Shigella with SE-1, in agreement with the hypothesis that SE-1 inhibited the expression of VirF-activated genes required for the formation of the T3SS apparatus and invasion. We found that the same concentrations of SE-1 had no detectable effects on the growth or metabolism of the bacterial cells or the eukaryotic host cells, respectively, indicating that the inhibition of invasion was not due to general toxicity. Overall, SE-1 appears to inhibit transcription activation by VirF, exhibits selectivity toward AraC family proteins, and has the potential to be developed into a novel antibacterial agent.


Assuntos
Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Quinolinas/metabolismo , Shigella flexneri/efeitos dos fármacos , Fatores de Transcrição/antagonistas & inibidores , Fatores de Virulência/antagonistas & inibidores , Animais , Linhagem Celular , DNA Bacteriano/metabolismo , Endocitose/efeitos dos fármacos , Escherichia coli/efeitos dos fármacos , Fibroblastos/efeitos dos fármacos , Fibroblastos/microbiologia , Perfilação da Expressão Gênica , Camundongos , Ligação Proteica/efeitos dos fármacos , Reação em Cadeia da Polimerase em Tempo Real , Ativação Transcricional/efeitos dos fármacos
2.
J Biomol Screen ; 18(5): 588-98, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23364515

RESUMO

Protein members of the AraC family of bacterial transcriptional activators have great promise as targets for the development of novel antibacterial agents. Here, we describe an in vivo high-throughput screen to identify inhibitors of the AraC family activator protein RhaS. The screen used two Escherichia coli reporter fusions: one to identify potential RhaS inhibitors and a second to eliminate nonspecific inhibitors from consideration. One compound with excellent selectivity, OSSL_051168, was chosen for further study. OSSL_051168 inhibited in vivo transcription activation by the RhaS DNA-binding domain to the same extent as the full-length protein, indicating that this domain was the target of its inhibition. Growth curves showed that OSSL_051168 did not affect bacterial cell growth at the concentrations used in this study. In vitro DNA-binding assays with purified protein suggest that OSSL_051168 inhibits DNA binding by RhaS. In addition, we found that it inhibits DNA binding by a second AraC family protein, RhaR, which shares 30% amino acid identity with RhaS. OSSL_051168 did not have a significant impact on DNA binding by the non-AraC family proteins CRP and LacI, suggesting that the inhibition is likely specific for RhaS, RhaR, and possibly additional AraC family activator proteins.


Assuntos
Antibacterianos/isolamento & purificação , Fator de Transcrição AraC/antagonistas & inibidores , Ensaios de Triagem em Larga Escala/métodos , Quinolinas/isolamento & purificação , Antibacterianos/química , Antibacterianos/farmacologia , Fator de Transcrição AraC/genética , Fator de Transcrição AraC/metabolismo , DNA Bacteriano/metabolismo , Relação Dose-Resposta a Droga , Descoberta de Drogas/métodos , Escherichia coli/efeitos dos fármacos , Escherichia coli/genética , Escherichia coli/crescimento & desenvolvimento , Escherichia coli/metabolismo , Proteínas de Escherichia coli/antagonistas & inibidores , Proteínas de Escherichia coli/metabolismo , Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Testes de Sensibilidade Microbiana , Modelos Biológicos , Família Multigênica , Ligação Proteica/efeitos dos fármacos , Quinolinas/química , Quinolinas/farmacologia , Bibliotecas de Moléculas Pequenas/análise , Transativadores/antagonistas & inibidores , Transativadores/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...